Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a Phase I clinical study for its universal NK cell therapy, GCK-01. This Category 1 innovative therapeutic biologic drug candidate is under development for the treatment of various hematological malignancies and solid tumor types, particularly in combination with antibody drugs and specifically for recurrent or chemotherapy-resistant follicular lymphoma (FL).
The current standard of care for recurrent or chemotherapy-resistant follicular lymphoma involves the combination of antibody with chemotherapy. GCK-01 is positioned as a potential first-in-class drug globally, offering a new approach to treatment for this patient population.- Flcube.com
